| Jul 30 |
NeuroBo Pharmaceuticals signs exclusive license agreement with Mthera Pharma
|
| Jul 30 |
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01
|
| Jul 17 |
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
|
| Jul 11 |
NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July
|
| Jul 1 |
NRBO: DA-1726 Shows Superiority to Survodutide in Pre-Clinical Models…
|
| Jun 27 |
NeuroBo doses first subject in Part 2 of Phase I obesity treatment trial
|
| Jun 26 |
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
|
| Jun 25 |
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
| Jun 24 |
NeuroBo Pharma prices private placement and direct offering to raise up to $70M
|
| Jun 24 |
NeuroBo Pharmaceuticals Announces Private Placement, Registered Direct Offering
|
